Horm Metab Res 2023; 55(12): 835-845
DOI: 10.1055/a-2167-0179
Original Article: Endocrine Care

Association Between Circulating Resistin Level and Preeclampsia: A Meta-Analysis

Xiangyu Xu
1   Department of Gynaecology and Obstetrics, Hangzhou Linping District First People’s Hospital, Hangzhou, China
Yi Du
1   Department of Gynaecology and Obstetrics, Hangzhou Linping District First People’s Hospital, Hangzhou, China
Ni Wang
1   Department of Gynaecology and Obstetrics, Hangzhou Linping District First People’s Hospital, Hangzhou, China
› Author Affiliations


Resistin, a diminutive secretory adipokine, has been linked to obesity and its related ailments. A growing body of evidence suggests that resistin may also be related to the pathogenesis preeclampsia. However, results of previous studies were not consistent. We performed a systematic review and meta-analysis to evaluate the level of circulating resistin in women with PE. A systematic search of Medline, Web of Science, and Embase databases from inception to April 28, 2023, was conducted to identify studies that compared blood resistin levels in pregnant women with and without PE. A random-effects model was utilized to pool the results, accounting for heterogeneity. The present study analyzed eighteen datasets from sixteen observational studies. The results of the meta-analysis demonstrated a statistically significant increase in blood resistin levels among women with PE compared to the control group. (standardized mean difference=0.35, 95% confidence interval: 0.16 to 0.54, p<0.001; I2=74%). The findings of the subgroup analysis indicate that various study characteristics, including study design, timing, and methods for measuring resistin, matching of body mass index between cases and controls, and study quality scores did not exert a significant impact on the outcomes. Nonetheless, it is noteworthy that the diagnostic criteria for PE employed in the studies included in the analysis may have influenced the results (p for subgroup difference=0.001). Women with preeclampsia exhibit a greater concentration of resistin in circulation when compared to healthy pregnant controls.

Publication History

Received: 16 June 2023

Accepted after revision: 28 August 2023

Article published online:
04 October 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Bokuda K, Ichihara A. Preeclampsia up to date – what’s going on?. Hypertens Res 2023; 1-8
  • 2 Robillard PY, Dekker G, Scioscia M. et al. Preeclampsia in 2023: time for preventing early onset- and term preeclampsia: The paramount role of gestational weight gain. J Reprod Immunol 2023; 158: 103968
  • 3 Ives CW, Sinkey R, Rajapreyar I. et al. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review. J Am Coll Cardiol 2020; 76: 1690-1702
  • 4 [Anonymous]. Gestational hypertension and preeclampsia: ACOG practice bulletin summary, Number 222. Obstet Gynecol 2020; 135: 1492-1495
  • 5 Rana S, Lemoine E, Granger JP. et al. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res 2019; 124: 1094-1112
  • 6 Seely EW, Celi AC, Chausmer J. et al. Cardiovascular health after preeclampsia: patient and provider perspective. J Womens Health (Larchmt) 2021; 30: 305-313
  • 7 Chappell LC, Cluver CA, Kingdom J. et al. Pre-eclampsia. Lancet 2021; 398: 341-354
  • 8 Ahmed B, Konje JC. The epidemiology of obesity in reproduction. Best Pract Res Clin Obstet Gynaecol 2023; 89: 102342
  • 9 Kabbani N, Bluher M, Stepan H. et al. Adipokines in pregnancy: a systematic review of clinical data. Biomedicines 2023; 11: 1419
  • 10 Abraham T, Romani AMP. The relationship between obesity and pre-eclampsia: incidental risks and identification of potential biomarkers for pre-eclampsia. Cells 2022; 11: 1548
  • 11 Acquarone E, Monacelli F, Borghi R. et al. Resistin: a reappraisal. Mech Ageing Dev 2019; 178: 46-63
  • 12 Shuldiner AR, Yang R, Gong DW.Resistin. obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345: 1345-1346
  • 13 Tripathi D, Kant S, Pandey S. et al. Resistin in metabolism, inflammation, and disease. FEBS J 2020; 287: 3141-3149
  • 14 Askin L, Abus S, Tanriverdi O. Resistin and cardiovascular disease: a review of the current literature regarding clinical and pathological relationships. Curr Cardiol Rev 2022; 18: e290721195114
  • 15 Zhou L, Li JY, He PP. et al. Resistin: potential biomarker and therapeutic target in atherosclerosis. Clin Chim Acta 2021; 512: 84-91
  • 16 Floeck A, Ferrari N, Joisten C. et al. Resistin in pregnancy: analysis of determinants in pairs of umbilical cord blood and maternal serum. Cytokine X 2021; 3: 100052
  • 17 Gutaj P, Sibiak R, Jankowski M. et al. The role of the adipokines in the most common gestational complications. Int J Mol Sci 2020; 21: 9408
  • 18 Haugen F, Ranheim T, Harsem NK. et al. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. Am J Physiol Endocrinol Metab 2006; 290: E326-E333
  • 19 Nanda S, Poon LC, Muhaisen M. et al. Maternal serum resistin at 11 to 13 weeks’ gestation in normal and pathological pregnancies. Metabolism 2012; 61: 699-705
  • 20 Song Y, Gao J, Qu Y. et al. Serum levels of leptin, adiponectin and resistin in relation to clinical characteristics in normal pregnancy and preeclampsia. Clin Chim Acta 2016; 458: 133-137
  • 21 Bawah AT, Yeboah FA, Nanga S. et al. Serum adipocytokines and adiposity as predictive indices of preeclampsia. Clin Hypertens 2020; 26: 19
  • 22 Banjac G, Ardalic D, Mihajlovic M. et al. The role of resistin in early preeclampsia prediction. Scand J Clin Lab Invest 2021; 81: 432-437
  • 23 Talab AY, Aboali Hamza H, Mostafa TM. Antepartum and postpartum changes in adipokines, endothelial dysfunction, inflammatory markers and other biochemical parameters in preeclamptic women: A prospective observational cohort study. J Appl Biomed 2021; 19: 62-72
  • 24 Saucedo R, Valencia-Ortega J, González-Reynoso R. et al. Altered maternal adipokine profile in preeclampsia. Ginecologia y Obstetricia de Mexico 2022; 90: 475-485
  • 25 Chandrasekaran S, Hunt H, Melhorn S. et al. Adipokine profiles in preeclampsia. J Matern Fetal Neonatal Med 2020; 33: 2812-2817
  • 26 Chen D, Dong M, Fang Q. et al. Alterations of serum resistin in normal pregnancy and pre-eclampsia. Clin Sci (Lond) 2005; 108: 81-84
  • 27 Cortelazzi D, Corbetta S, Ronzoni S. et al. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol (Oxf) 2007; 66: 447-453
  • 28 Seol HJ, Oh MJ, Yeo MK. et al. Comparison of serum levels and the placental expression of resistin between patients with preeclampsia and normal pregnant women. Hypertens Pregnancy 2010; 29: 310-317
  • 29 Weedon MS, Sheng Y, Sugulle M. et al. Placental miR-1301 is dysregulated in early-onset preeclampsia and inversely correlated with maternal circulating leptin. Placenta 2014; 35: 709-717
  • 30 Christiansen M, Hedley PL, Placing S. et al. Maternal serum resistin is reduced in first trimester preeclampsia pregnancies and is a marker of clinical severity. Hypertens Pregnancy 2015; 34: 422-433
  • 31 Erol O, Suren D, Ellidag HY. et al. Serum level and placental expression of resistin in pregnancies complicated by preeclampsia: relationship with disease severity. Clin Exp Obstet Gynecol 2016; 43: 516-521
  • 32 Camacho E, Matos MG, Pastorello M. et al. Circulating resistin in venezuelan healthy pregnant women or with preeclampsia. Revis Latinoam Hipertens 2018; 13: 316-322
  • 33 Lomakova YD, Chen X, Stein TP. et al. Decreased adiponectin levels in early pregnancy are associated with high risk of prematurity for African American women. J Clin Med 2022; 11: 3213
  • 34 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
  • 35 Page MJ, Moher D, Bossuyt PM. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372: n160
  • 36 Higgins J, Thomas J, Chandler J. et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration. 2021 www.training.cochrane.org/handbook
  • 37 Wells GA, Shea B, O’Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  • 38 Higgins J, Green S. Cochrane Handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011 www.cochranehandbook.org
  • 39 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
  • 40 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
  • 41 [Anonymous]. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77: 67-75
  • 42 Brown MA, Lindheimer MD, de Swiet M. et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV
  • 43 [Anonymous]. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol 2013; 122: 1122-1131
  • 44 Tranquilli AL, Dekker G, Magee L. et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens 2014; 4: 97-104
  • 45 Bouter AR, Duvekot JJ. Evaluation of the clinical impact of the revised ISSHP and ACOG definitions on preeclampsia. Pregnancy Hypertens 2020; 19: 206-211
  • 46 Yannakoulia M, Yiannakouris N, Bluher S. et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003; 88: 1730-1736
  • 47 Taouis M, Benomar Y. Is resistin the master link between inflammation and inflammation-related chronic diseases?. Mol Cell Endocrinol 2021; 533: 111341
  • 48 Huang X, Yang Z. Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest 2016; 39: 607-615
  • 49 Li Y, Yang Q, Cai D. et al. Resistin, a novel host defense peptide of innate immunity. Front Immunol 2021; 12: 699807
  • 50 Robertson SA, Rae CJ, Graham A. Resistin: TWEAKing angiogenesis. Atherosclerosis 2009; 203: 34-37